Clinical Trials Logo

Clinical Trial Summary

This study will be conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05113771
Study type Interventional
Source Denovo Biopharma LLC
Contact Robbie Alton
Phone 858-799-1021
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date March 2022
Completion date April 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04124341 - EpCS in Severe Treatment Resistant Depression N/A
Recruiting NCT03887715 - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression N/A
Recruiting NCT04727229 - Stellate Ganglion Block for Major Depressive Disorder. Phase 4
Enrolling by invitation NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD Phase 2
Withdrawn NCT03175887 - Investigational TMS Treatment for Depression N/A
Completed NCT03134066 - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting NCT01984710 - DBS for TRD Medtronic Activa PC+S N/A
Completed NCT01935115 - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Phase 4
Terminated NCT01687478 - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Phase 3
Completed NCT00531726 - Berlin Deep Brain Stimulation Depression Study N/A
Active, not recruiting NCT04739865 - The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression Phase 2
Not yet recruiting NCT04099342 - Enhanced Spatial Targeting in ECT Utilizing FEAST N/A
Recruiting NCT04041479 - Biomarker-guided rTMS for Treatment Resistant Depression Phase 3
Recruiting NCT04959253 - Psilocybin in Depression Resistant to Standard Treatments Phase 2
Completed NCT04856124 - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting NCT03272698 - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression Phase 4
Recruiting NCT04451135 - CET- REM (Correlating ECT Response to EEG Markers) N/A
Recruiting NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Terminated NCT02675556 - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression Phase 1
Recruiting NCT04504175 - Ketamine for Older Adults Pilot Phase 4